Baxter Bros Inc’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.54M | Sell |
39,184
-455
| -1% | -$38.1K | 0.41% | 52 |
|
|
2026
Q1 | $3.17M | Sell |
39,639
-3,576
| -8% | -$295K | 0.39% | 56 |
|
|
2025
Q4 | $3.68M | Sell |
43,215
-2,321
| -5% | -$190K | 0.43% | 47 |
|
|
2025
Q3 | $3.54M | Sell |
45,536
-3,625
| -7% | -$283K | 0.41% | 52 |
|
|
2025
Q2 | $3.84M | Sell |
49,161
-28,075
| -36% | -$2.09M | 0.47% | 45 |
|
|
2025
Q1 | $5.6M | Sell |
77,236
-10,588
| -12% | -$758K | 0.74% | 36 |
|
|
2024
Q4 | $6.5M | Buy |
87,824
+2,556
| +3% | +$179K | 0.85% | 36 |
|
|
2024
Q3 | $5.63M | Buy |
85,268
+1,510
| +2% | +$110K | 0.73% | 35 |
|
|
2024
Q2 | $7.74M | Sell |
83,758
-3,261
| -4% | -$289K | 1.01% | 25 |
|
|
2024
Q1 | $8.32M | Sell |
87,019
-3,493
| -4% | -$293K | 1.07% | 24 |
|
|
2023
Q4 | $6.9M | Buy |
90,512
+5,985
| +7% | +$416K | 0.96% | 29 |
|
|
2023
Q3 | $5.86M | Buy |
84,527
+3,325
| +4% | +$267K | 0.89% | 28 |
|
|
2023
Q2 | $7.66M | Sell |
81,202
-887
| -1% | -$77.1K | 1.14% | 25 |
|
|
2023
Q1 | $6.79M | Sell |
82,089
-369
| -0.4% | -$29K | 1.07% | 28 |
|
|
2022
Q4 | $6.15M | Sell |
82,458
-2,170
| -3% | -$167K | 1.01% | 30 |
|
|
2022
Q3 | $6.99M | Sell |
84,628
-2,495
| -3% | -$240K | 1.24% | 23 |
|
|
2022
Q2 | $8.29M | Sell |
87,123
-1,665
| -2% | -$172K | 1.49% | 18 |
|
|
2022
Q1 | $10.5M | Sell |
88,788
-660
| -0.7% | -$74K | 1.57% | 19 |
|
|
2021
Q4 | $11.6M | Sell |
89,448
-1,015
| -1% | -$118K | 1.68% | 21 |
|
|
2021
Q3 | $10.2M | Sell |
90,463
-2,145
| -2% | -$245K | 1.64% | 19 |
|
|
2021
Q2 | $9.59M | Buy |
92,608
+403
| +0.4% | +$38K | 1.52% | 20 |
|
|
2021
Q1 | $7.71M | Sell |
92,205
-4,740
| -5% | -$401K | 1.32% | 22 |
|
|
2020
Q4 | $8.84M | Sell |
96,945
-3,655
| -4% | -$303K | 1.68% | 18 |
|
|
2020
Q3 | $8.03M | Sell |
100,600
-3,180
| -3% | -$248K | 1.74% | 17 |
|
|
2020
Q2 | $7.17M | Sell |
103,780
-2,270
| -2% | -$161K | 1.68% | 17 |
|
|
2020
Q1 | $6.67M | Sell |
106,050
-4,620
| -4% | -$333K | 1.73% | 15 |
|
|
2019
Q4 | $8.61M | Sell |
110,670
-300
| -0.3% | -$23.4K | 1.79% | 17 |
|
|
2019
Q3 | $8.13M | Sell |
110,970
-1,230
| -1% | -$86.4K | 1.84% | 18 |
|
|
2019
Q2 | $6.91M | Sell |
112,200
-4,725
| -4% | -$286K | 1.58% | 21 |
|
|
2019
Q1 | $7.46M | Sell |
116,925
-5,217
| -4% | -$298K | 1.74% | 18 |
|
|
2018
Q4 | $6.24M | Sell |
122,142
-6,594
| -5% | -$334K | 1.69% | 18 |
|
|
2018
Q3 | $7.47M | Buy |
128,736
+600
| +0.5% | +$29.3K | 1.79% | 16 |
|
|
2018
Q2 | $6.22M | Buy |
128,136
+420
| +0.3% | +$19.6K | 1.67% | 18 |
|
|
2018
Q1 | $5.94M | Buy |
127,716
+10,959
| +9% | +$476K | 1.62% | 16 |
|
|
2017
Q4 | $4.39M | Buy |
116,757
+27,840
| +31% | +$1.02M | 1.2% | 26 |
|
|
2017
Q3 | $3.24M | Buy |
88,917
+11,070
| +14% | +$422K | 0.93% | 35 |
|
|
2017
Q2 | $3.07M | Buy |
77,847
+24,150
| +45% | +$881K | 0.92% | 34 |
|
|
2017
Q1 | $1.68M | Buy |
+53,697
| New | +$1.68M | 0.53% | 44 |
|
Other funds holding EW
Baxter Bros Inc's EW Position: Q2 2026 in Review
Baxter Bros Inc reduced its Edwards Lifesciences (EW) stake by 1.1% in Q2 2026, selling an estimated $38.1K and leaving 39,184 shares worth $3.54M. The position accounts for 0.41% of the portfolio, ranked #52.
Baxter Bros Inc first reported a position in EW in Q1 2017 and has held it in 38 quarters since. The position peaked at $11.6M in Q4 2021. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Baxter Bros Inc held 39,184 shares of Edwards Lifesciences worth $3.54M as of Q2 2026.
- Baxter Bros Inc sold 455 Edwards Lifesciences shares in Q2 2026, an estimated $38.1K.
- Edwards Lifesciences made up 0.41% of Baxter Bros Inc's portfolio in Q2 2026, its #52 holding.
- Baxter Bros Inc first reported a position in Edwards Lifesciences in Q1 2017 and has held it in 38 quarters since.
- Baxter Bros Inc's Edwards Lifesciences position peaked at $11.6M in Q4 2021.
- 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Baxter Bros Inc's 13F filing for Q2 2026, filed 6 Aug 2026.